Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis (original) (raw)
Article navigation
Research Articles| October 06 2009
aEppendorf University Hospital, Hamburg, and bHospital Biederstein, Technical University, Munich, Germany; cUniversity Hospital, Rotterdam/Sophia, The Netherlands; dBordeaux Children’s Hospital, Bordeaux, and eNantes University Hospital, Nantes, France
Search for other works by this author on:
aEppendorf University Hospital, Hamburg, and bHospital Biederstein, Technical University, Munich, Germany; cUniversity Hospital, Rotterdam/Sophia, The Netherlands; dBordeaux Children’s Hospital, Bordeaux, and eNantes University Hospital, Nantes, France
Search for other works by this author on:
aEppendorf University Hospital, Hamburg, and bHospital Biederstein, Technical University, Munich, Germany; cUniversity Hospital, Rotterdam/Sophia, The Netherlands; dBordeaux Children’s Hospital, Bordeaux, and eNantes University Hospital, Nantes, France
Search for other works by this author on:
aEppendorf University Hospital, Hamburg, and bHospital Biederstein, Technical University, Munich, Germany; cUniversity Hospital, Rotterdam/Sophia, The Netherlands; dBordeaux Children’s Hospital, Bordeaux, and eNantes University Hospital, Nantes, France
Search for other works by this author on:
aEppendorf University Hospital, Hamburg, and bHospital Biederstein, Technical University, Munich, Germany; cUniversity Hospital, Rotterdam/Sophia, The Netherlands; dBordeaux Children’s Hospital, Bordeaux, and eNantes University Hospital, Nantes, France
Search for other works by this author on:
aEppendorf University Hospital, Hamburg, and bHospital Biederstein, Technical University, Munich, Germany; cUniversity Hospital, Rotterdam/Sophia, The Netherlands; dBordeaux Children’s Hospital, Bordeaux, and eNantes University Hospital, Nantes, France
Search for other works by this author on:
Dermatology (1997) 195 (1): 10–19.
Accepted:
November 28 1996
Published Online:
October 06 2009
Abstract
Background: We have previously reported how the SCORAD index was designed. This cumulative index combines objective (extent and intensity of lesions) and subjective (daytime pruritus and sleep loss) criteria. Aims: To study interobserver variability in scoring for objective SCORAD criteria and to optimize the scoring guidelines. Material and Methods: Three scoring sessions were organized in 1993-1994 in Hamburg, Bordeaux and Rotterdam totalizing 19 patients (14 children and 5 adults) and 23 physicians, among whom 12 participated in at least 2 scoring sessions; 169 evaluation sheets have been processed using the SCORAD File Marker Pro software. At each session, total body photographs and close-up views were taken of each patient, and this material was reviewed at the final evaluation. Results: The extent of lesions according to the rule of nines showed interobserver variability mostly for patients with lesions of moderate intensity involving 20–60% of body surface. Intensity items were scored with more consistency overall, but variations subsided especially for oozing/crusts and lichenifications. Low and high scorer profiles and the benefit of training were noted. Conclusions: This study has allowed to optimize clinical scoring using the SCORAD system. A proposal has been made to grade the severity of atopic dermatitis according to objective criteria in three groups for inclusion in clinical trials. The SCORAD index remains the major criterion for follow-up in trials.
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.